The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|September 11, 2020
Tjoapack to Invest in Automated Injectables Packaging Capabilities
Author(s)Pharmaceutical Technology Editors
Tjoapack is investing in fully automated lines, including a PFS line with an initial capacity of 7 million syringes per year and a vial line with an eventual capacity of more than 12 million vials per year.
Advertisement
Tjoapack, a contract packaging organization, announced on Sept. 10, 2020 that it is investing in automated injectables packaging capabilities to meet customer demands for prefilled syringes (PFS) and vials.
A new, fully automated PFS line features an initial capacity of 7 million syringes per year and has the ability to assemble, automate insertion of plunger rods and back-stops, carry out inline labelling, and complete coding and vision control, a company press release said. It will be fully operational by the fourth quarter of 2021. A fully automated vial line will begin operations in the first quarter of 2021 and will increase its capacity to over 12 million vials per year.
“As new therapies emerge to address unmet patient needs for chronic ailments the demand for contract packaging organization[s] that can handle syringes and vials will continue to rise,” said Dexter Tjoa, CEO, Tjoapack, in the press release. “Technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market will also further propel the needs for service providers who can meet these requirements.”
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement